145 related articles for article (PubMed ID: 17504878)
1. Identification and evaluation of a new tumor cell-binding peptide, FROP-1.
Zitzmann S; Krämer S; Mier W; Hebling U; Altmann A; Rother A; Berndorff D; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Jun; 48(6):965-72. PubMed ID: 17504878
[TBL] [Abstract][Full Text] [Related]
2. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of a peptide with affinity to head and neck cancer.
Nothelfer EM; Zitzmann-Kolbe S; Garcia-Boy R; Krämer S; Herold-Mende C; Altmann A; Eisenhut M; Mier W; Haberkorn U
J Nucl Med; 2009 Mar; 50(3):426-34. PubMed ID: 19223422
[TBL] [Abstract][Full Text] [Related]
4. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
5. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of the breast cancer cell-binding peptide, p160.
Askoxylakis V; Zitzmann S; Mier W; Graham K; Krämer S; von Wegner F; Fink RH; Schwab M; Eisenhut M; Haberkorn U
Clin Cancer Res; 2005 Sep; 11(18):6705-12. PubMed ID: 16166451
[TBL] [Abstract][Full Text] [Related]
7. PEGylation enables the specific tumor accumulation of a peptide identified by phage display.
Mier W; Krämer S; Zitzmann S; Altmann A; Leotta K; Schierbaum U; Schnölzer M; Eisenhut M; Haberkorn U
Org Biomol Chem; 2013 Apr; 11(16):2706-11. PubMed ID: 23474823
[TBL] [Abstract][Full Text] [Related]
8. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
[TBL] [Abstract][Full Text] [Related]
9. Localization of iodine-125-mIP-Des-Met14-bombesin (7-13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer.
Rogers BE; Rosenfeld ME; Khazaeli MB; Mikheeva G; Stackhouse MA; Liu T; Curiel DT; Buchsbaum DJ
J Nucl Med; 1997 Aug; 38(8):1221-9. PubMed ID: 9255155
[TBL] [Abstract][Full Text] [Related]
10.
Ahmadpour S; Noaparast Z; Abedi SM; Hosseinimehr SJ
Anticancer Agents Med Chem; 2018; 18(9):1295-1302. PubMed ID: 29521248
[TBL] [Abstract][Full Text] [Related]
11. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
12. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics.
Haubner R; Wester HJ; Burkhart F; Senekowitsch-Schmidtke R; Weber W; Goodman SL; Kessler H; Schwaiger M
J Nucl Med; 2001 Feb; 42(2):326-36. PubMed ID: 11216533
[TBL] [Abstract][Full Text] [Related]
13. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
15. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
16. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
Petrich T; Helmeke HJ; Meyer GJ; Knapp WH; Pötter E
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):842-54. PubMed ID: 12111124
[TBL] [Abstract][Full Text] [Related]
17. Identification of a new prostate-specific cyclic peptide with the bacterial FliTrx system.
Zitzmann S; Krämer S; Mier W; Mahmut M; Fleig J; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2005 May; 46(5):782-5. PubMed ID: 15872351
[TBL] [Abstract][Full Text] [Related]
18. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.
Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC
Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459
[TBL] [Abstract][Full Text] [Related]
19. Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma.
Yu M; Zhou H; Liu X; Huo Y; Zhu Y; Chen Y
Ann Nucl Med; 2010 Jan; 24(1):13-9. PubMed ID: 19997991
[TBL] [Abstract][Full Text] [Related]
20. Characterization and development of a peptide (p160) with affinity for neuroblastoma cells.
Askoxylakis V; Mier W; Zitzmann S; Ehemann V; Zhang J; Krämer S; Beck C; Schwab M; Eisenhut M; Haberkorn U
J Nucl Med; 2006 Jun; 47(6):981-8. PubMed ID: 16741308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
